Details of the Drug Combination

General Information of Drug Combination (ID: DCIOPFN)

Drug Combination Name
Droperidol Betamethasone
Indication
Disease Entry Status REF
Postoperative Vomiting Phase 3 [1]
Component Drugs Droperidol   DM0DXA8 Betamethasone   DMAHJEF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Droperidol
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [2]
Droperidol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Binder [5]
------------------------------------------------------------------------------------
Droperidol Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Increases ADR [6]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Increases ADR [6]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Increases ADR [6]
------------------------------------------------------------------------------------
Indication(s) of Betamethasone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [3]
Addison disease 5A74.0 Approved [3]
Allergic rhinitis CA08.0 Approved [3]
Angioedema 4A00.15 Approved [3]
Aspiration pneumonitis N.A. Approved [3]
Autoimmune haemolytic anaemia 3A20 Approved [3]
Bursitis N.A. Approved [3]
Cerebral edema 8D60.1 Approved [3]
Congenital adrenal hyperplasia 5A71.01 Approved [3]
Crohn disease DD70 Approved [3]
Dermatitis herpetiformis EB44 Approved [3]
Diamond-Blackfan anemia N.A. Approved [3]
Disorder of orbital region N.A. Approved [3]
Epicondylitis N.A. Approved [3]
Erythema multiforme N.A. Approved [3]
Exanthem N.A. Approved [3]
Granuloma annulare N.A. Approved [3]
Inflammation 1A00-CA43.1 Approved [4]
Inflammatory bowel disease DD72 Approved [3]
Miliary tuberculosis N.A. Approved [3]
Multiple sclerosis 8A40 Approved [3]
Mycosis fungoides 2B01 Approved [3]
Primary cutaneous T-cell lymphoma N.A. Approved [3]
Psoriasis EA90 Approved [3]
Psoriatic arthritis FA21 Approved [3]
Rheumatic heart disease N.A. Approved [3]
Sarcoidosis 4B20.5 Approved [3]
Scalp dermatosis N.A. Approved [3]
Serum sickness N.A. Approved [3]
Severe asthma CA23 Approved [3]
Skin disease EA00-EM0Z Approved [3]
Systemic lupus erythematosus 4A40.0 Approved [3]
Tinea corporis 1F28.Y Approved [3]
Tinea cruris 1F28.3 Approved [3]
Acquired thrombocytopenia N.A. Investigative [3]
Asthma CA23 Investigative [3]
Beta-thalassemia major N.A. Investigative [3]
Classic Hodgkin lymphoma N.A. Investigative [3]
Follicular lymphoma 2A80 Investigative [3]
Rheumatoid arthritis FA20 Investigative [3]
Synovitis N.A. Investigative [3]
Tinea pedis 1F28.2 Investigative [3]
Trichinellosis N.A. Investigative [3]
Betamethasone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Agonist [8]
------------------------------------------------------------------------------------
Betamethasone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Betamethasone Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Frataxin, mitochondrial (FXN) OTE9U09A FRDA_HUMAN Increases Expression [10]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [7]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [7]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02744495) Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7172).
3 Betamethasone FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7061).
5 Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
8 The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83.
9 Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
10 Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.